Search results for #PHERGain
📢 Exciting news! Our #PHERGain trial results on [18F]FDG PET/CT cutoff for HER2-positive breast cancer patients treated with trastuzumab and pertuzumab are out in @JournalofNucMed
Another recognition for the #PHERGain trial, this time for an exploratory analysis in European Journal of Nuclear Medicine and Molecular Imaging (@SpringerHealth ). You can access the publication here: link.springer.com/article/10.100… #EJNMMI #BreastCancerResearch #innovation
At #AACR24, we have presented the results poster of METSGain, a #PHERGain sub-study in collaboration with @RevealGenomics. Presentation Number: 5213/21 Presented by: Mario Mancino Download the poster here: …6-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_afb… #AACR24 #Oncology #Research
Dr. @JavierCortesMD presented the #PHERGain 3-year disease-free survival results at #ASCO23 and, following @TheLancet publication, emphasized the achievements attained in this study. Learn more about the study: medsir.org/post/revolutio… #MEDSIRtheLancet #OncologyResearch
Dr. Antonio Llombart, MEDSIR Medical Associates and Scientific Leaders of the #PHERGain trial highlights the trial after its publication in @TheLancet. Read the publication in The Lancet: thelancet.com/journals/lance… #BreastCancer #OncologyResearch #cancerresearch #clinicaltrials
Dr. José Pérez, MEDSIR Medical Associate and Deputy Director at the International Breast Cancer Center, and a key figure in the #PHERGain trial, underscores the importance of its publication in @TheLancet, a leading global academic journal. #BreastCancer #OncologyResearch
👉 @TheLancet publica los resultados del ensayo clínico #PHERGain, desarrollado por MEDSIR, en los que se demuestra que un tercio de las pacientes con #cáncerdemama HER2 positivo localizado podrían ser curadas sin quimioterapia @wearemedsir @MSDEspana 👉n9.cl/jezoz
No todos los días se tiene un reconocimiento internacional como esta publicación en The Lancet que resalta la relevancia del estudio #Phergain y su potencial impacto en la calidad de vida de pacientes de todo el mundo. Enorme mérito y trabajo de todo el equipo Medsir.
No todos los días se tiene un reconocimiento internacional como esta publicación en The Lancet que resalta la relevancia del estudio #Phergain y su potencial impacto en la calidad de vida de pacientes de todo el mundo. Enorme mérito y trabajo de todo el equipo Medsir.
#PHERGain trial displays promising results in HER2-positive early breast cancer treatment, opening doors to a chemotherapy-free approach, lightening the treatment load for patients. Learn more: medsir.org/post/revolutio…
The #PHERGain trial results, presented at ASCO 2023, have been published in @TheLancet, highlighting the study's relevance. Read the paper: thelancet.com/journals/lance… #BreastCancer #OncologyResearch #ClinicalTrials
Recurrence data from the #PHERGain phase 2 trial published on @TheLancet. A de-escalated, PET-response-based neoadjuvant treatment strategy for stage I-IIIA HER2+ breast cancer led to 94.8% 3-year iDFS rate and halved the incidence of severe AEs. #bcsm thelancet.com/journals/lance…
Exciting news! We are attending @AACR , can't wait to connect with you! We present two of our translational studies, transFAL, a sub-study of #PARSIFALtrial, and METSGain, a substudy of #PHERGain. Discover more medsir.org/aacr-2024 See you there! #AACR24 #Oncology #Research
We are delighted to announce the publication of the #PHERGain substudy in Breast Cancer Research and treatment (@SpringerHealth). You can access the publication here: link.springer.com/article/10.100… #Biomarkers #BreastCancerResearch #innovation
Global cancer challenge demands innovative detection & treatment strategies. #Biomarkers provide key insights into risk, progression, & treatment efficacy. Explore how MEDSIR advances biomarker research in oncology. #PHERGain #Innovation #research medsir.org/post/biomarker…
Dr. @maria_gion highlighted the translational findings from #PHERGain at #ESMO23, emphasizing the identification of future treatment benefits for HER2+ patientsWatch the interview: youtube.com/watch?v=yfX7J-… #CancerResearch #ClinicalTrials #Oncology #BringYourIdeaToLife #Trop2
Dr. Antonio Llombart highlighted #PHERGain's crucial translational study. Teaming up with @RevealGenomics, Dr. Llombart explores #HER2DX's potential for personalized breast cancer treatment. Full interview: youtube.com/watch?v=cGvLjG… #CancerReseacrh #ClinicalTrials #Oncology
@maria_gion emphasized the importance of biomarkers like Trop-2 in #PHERGain's translational studies during the #ESMO23 congress. #ESMO23 #CancerReseacrh #ClinicalTrials #Oncology #Bringyourideatolife
At the 2023 @ASCO Annual Meeting, @JavierCortesMD discussed results from the #PHERGain study. Learn more here: hmpgloballearningnetwork.com/site/onc/video… #medtwitter #onctwitter #ASCO23
